August 1, 1989HeartOpen Access

Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics.

View Full Paper

Ask AI

Bookmark

Why the study?

Does flecainide terminate and prevent recurrent supraventricular tachycardia in children?

Population

23 children with recurrent supraventricular tachycardia

Design

Case_series

Authors

JTJan TillNational Health Service ESE A ShinebourneOslo University Hospital EREdward RowlandElectrophysiology

Discussion

Member takes

Implication

May support flecainide for pediatric SVT; hypothesis-generating from case data and requires prospective trials before practice change.

Structured PICO

Does flecainide terminate and prevent recurrent supraventricular tachycardia in children?

Population

23 children with recurrent supraventricular tachycardia

Intervention

Flecainide (intravenous 2 mg/kg over 10 minutes for acute attacks, and/or oral preparation for long-term prevention)

Outcome

Termination of tachycardia (acute) and prevention of further attacks (long-term), along with pharmacokinetic variables

Flecainide is effective for terminating and preventing supraventricular tachycardia in children, but requires careful initiation in hospital due to potential arrhythmogenic effects.

Cite This Study

Till et al. (1989) studied this question.

synapsesocial.com/papers/6a82a7185bcab2ccdb8d6413 https://doi.org/10.1136/hrt.62.2.133

View Full Paper

Ask AI

Bookmark

Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Paediatric use of flecainide in supraventricular tachycardia: clinical efficacy and pharmacokinetics.

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider